



FOR IMMEDIATE RELEASE:

EyeGate Pharma to Present at Upcoming Biotechnology Industry Conferences

Waltham, MA, – June 11, 2008 – EyeGate Pharma, a privately held, specialty pharmaceutical company using iontophoresis technology to safely and non-invasively deliver therapeutics into the front and back of the eye to treat serious ocular diseases, today announced that Remis Bistras, Ph.D., Vice President, Business Development, will present at two upcoming biotechnology conferences. Dr. Bistras will be available for one-on-one meetings during these conferences.

Medtech Insight's In3 Medical Device Summit takes place June 17-19, 2008 in San Francisco, CA. Dr. Bistras' presentation is scheduled on June 18 at 2:20 PM. For more information, visit http://www.windhover.com/mti/template.asp?page=in3_summit08&eventID=11

The *BIO 2008 International Convention* takes place June 17-20, 2008 in San Diego, CA. Dr. Bistras' presentation is scheduled for Friday, June 20 at 10:45-11:00 AM in room 5B. He will also be participating in the BIO Business Forum. For more information, visit <http://www.bio2008.org/>

About EyeGate Pharma

EyeGate Pharma recently initiated a Phase I clinical study designed to assess the safety and tolerability of the non-invasive EyeGate® II Ocular Drug Delivery System and plans to initiate Phase 2 clinical trials in the first half 2008 in uveitis and later in dry eye. EyeGate was founded in 1999 with technology licensed from Bascom Palmer Eye Institute at the University of Miami. EyeGate's transscleral (white membrane of the eye) iontophoresis delivery platform, the EyeGate® II Delivery System, was developed to safely deliver a wide range of therapeutics to both the anterior (front) and posterior (back) chambers of the eye. For more information please visit www.eyegatepharma.com.

#

IR/PR Contact:

Bryan Murphy or Tim Allison
LaVoie Group
978-745-4200 X105 or X102
bmurphy@lavoiegroup.com or
tallison@lavoiegroup.com